Please check your internet connection and try again.
# Montelukast-Levocetirizine
## Overview
This combination (often seen as a combination tablet or as two separate adjunct agents) utilizes a leukotriene receptor antagonist (montelukast) and a second-generation H1-antihistamine (levocetirizine) to manage allergic inflammatory conditions.
## Primary Indications
* Allergic rhinitis (perennial and seasonal).
* Chronic urticaria.
* Adjunct therapy for asthma (montelukast component only).
## Adult Dosing
* **Montelukast:** 10 mg orally once daily in the evening.
* **Levocetirizine:** 5 mg orally once daily in the evening.
## Pediatric Dosing
* **6 to 14 years:** Montelukast 5 mg (chewable) daily + Levocetirizine 2.5 mg daily.
* **6 months to 5 years:** Montelukast 4 mg (granules/chewable) daily + Levocetirizine 1.25 mg daily.
* *Note:* Dosing for children < 6 months is not standardized; consult specialist guidelines.
## Dose Adjustments
* **Renal Impairment (Levocetirizine):** Requires dosage modification for CrCl < 80 mL/min.
* CrCl 50–80 mL/min: 2.5 mg daily.
* CrCl 30–50 mL/min: 1.25 mg daily.
* CrCl < 30 mL/min: Use generally discouraged; avoid if possible.
* **Hepatic Impairment:** No standard adjustment for montelukast; use caution in severe impairment.
## Contraindications
* Hypersensitivity to montelukast, levocetirizine, or any component of the formulation.
* End-stage renal disease (CrCl < 10 mL/min) or patients undergoing hemodialysis (levocetirizine).
## Adverse Effects
* **Neuropsychiatric (Montelukast BBW):** Agitation, aggression, depression, sleep disturbances, and suicidal ideation.
* **General:** Somnolence, fatigue, dry mouth, and headache (most frequent with levocetirizine).
* **Rare:** Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis).
## Key Drug Interactions
* **CNS Depressants:** Avoid concomitant use with alcohol, benzodiazepines, or opioids due to additive sedation from levocetirizine.
* **CYP450 Inducers:** Phenobarbital, phenytoin, and rifampin may decrease montelukast concentrations.
* **P-glycoprotein inhibitors:** May increase plasma levels of components.
## Monitoring
* Monitor for neuropsychiatric changes (mood/behavior) in patients taking montelukast.
* Monitor for sedation or impaired alertness, especially during initial therapy.
* Renal function (CrCl) baseline and periodically if on long-term levocetirizine therapy.
## Clinical Pearls
* **Timing:** Administer in the evening to optimize control of nocturnal allergic symptoms and to mitigate daytime somnolence associated with levocetirizine.
* **Black Box Warning:** The FDA requires a warning for montelukast regarding serious neuropsychiatric events. Limit use to cases where other options are ineffective or inappropriate.
* **Asthma:** Montelukast is not indicated for the reversal of bronchospasm in acute asthma exacerbations.
* **Formulation:** Granules may be administered directly in the mouth, dissolved in cold/room temperature baby formula or breast milk (not water), or mixed with a spoonful of soft food (applesauce, carrots, rice). Use within 15 minutes of opening the packet.
***
*Disclaimer: This information is for educational purposes for licensed healthcare professionals. Always verify current, site-specific prescribing information, FDA-approved labels, and clinical guidelines before prescribing or administering medications.*
